These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23935912)

  • 21. KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.
    Tímár J; Hegedüs B; Rásó E
    Curr Cancer Drug Targets; 2010 Dec; 10(8):813-23. PubMed ID: 20718705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
    Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
    J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
    Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
    Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.
    Kamel-Reid S; Zhang T; Persons DL; Nikiforova MN; Halling KC;
    Arch Pathol Lab Med; 2012 Jan; 136(1):26-32. PubMed ID: 22208484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.
    Chretien AS; Harlé A; Meyer-Lefebvre M; Rouyer M; Husson M; Ramacci C; Harter V; Genin P; Leroux A; Merlin JL
    Cancer Med; 2013 Feb; 2(1):11-20. PubMed ID: 24133623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
    Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
    Dono M; Massucco C; Chiara S; Sonaglio C; Mora M; Truini A; Cerruti G; Zoppoli G; Ballestrero A; Truini M; Ferrarini M; Zupo S
    Mol Med; 2013 Feb; 18(1):1519-26. PubMed ID: 23255073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.
    Monzon FA; Ogino S; Hammond ME; Halling KC; Bloom KJ; Nikiforova MN
    Arch Pathol Lab Med; 2009 Oct; 133(10):1600-6. PubMed ID: 19792050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.
    Bellon E; Ligtenberg MJ; Tejpar S; Cox K; de Hertogh G; de Stricker K; Edsjö A; Gorgoulis V; Höfler G; Jung A; Kotsinas A; Laurent-Puig P; López-Ríos F; Hansen TP; Rouleau E; Vandenberghe P; van Krieken JJ; Dequeker E
    Oncologist; 2011; 16(4):467-78. PubMed ID: 21441573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
    Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
    J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
    Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
    van Krieken JH; Jung A; Kirchner T; Carneiro F; Seruca R; Bosman FT; Quirke P; Fléjou JF; Plato Hansen T; de Hertogh G; Jares P; Langner C; Hoefler G; Ligtenberg M; Tiniakos D; Tejpar S; Bevilacqua G; Ensari A
    Virchows Arch; 2008 Nov; 453(5):417-31. PubMed ID: 18802721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
    Hoorens A; Jouret-Mourin A; Sempoux C; Demetter P; De Hertogh G; Teugels E
    Acta Gastroenterol Belg; 2010; 73(4):497-503. PubMed ID: 21299161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
    Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
    [No Abstract]   [Full Text] [Related]  

  • 37. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.
    Kristensen LS; Kjeldsen TE; Hager H; Hansen LL
    BMC Cancer; 2012 Nov; 12():548. PubMed ID: 23173730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutation testing in colorectal cancer.
    Plesec TP; Hunt JL
    Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
    Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.